AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12562722
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg nightly for 7 days before IOS dose
Trial: 12562722
Drug: Itraconazole oral
RxNorm normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral solution (IOS) 400 mg
Trial: 11059872
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy for 12 months
Trial: 11059872
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy for 6 months
Trial: 8473720
Drug: moclobemide 200
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moclobemide 200 mg
Trial: 8473720
Drug: moclobemide 400
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moclobemide 400 mg
Trial: 27508319
Drug: fat-modified diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fat-modified diet plus cholestyramine (8 g twice daily)
Trial: 24797765
Drug: Additional educational
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional educational material (SAGA tool) in treatment-naïve patients
Trial: 24797765
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment in treatment-naïve patients
Trial: 18265446
Drug: New platelet
RxNorm normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New platelet products using platelet additive solutions
Trial: 14759085
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus 100 mg/day ASA (group A, n = 70)
Trial: 14759085
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day ASA alone (group B, n = 70)
Trial: 9338539
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate powder (250 microg twice daily)
Trial: 9338539
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide aerosol (200 microg four times daily)
Trial: 8081133
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of early amniotomy and early oxytocin
Trial: 30953543
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) every 6 hours until 16 administrations or ICU discharge.
Trial: 27829367
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg IN ketamine
Trial: 27829367
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg IM morphine
Trial: 22314136
Drug: Measles vaccine
RxNorm normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles vaccine at 4 months of age
Trial: 22314136
Drug: Measles vaccine
RxNorm normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles vaccine at 9 months of age (group 1)
Trial: 15940126
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 50 microg LPS
Trial: 15940126
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone 20 mg/d for 6 days
Trial: 11752998
Drug: Intrathecal adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal adenosine (0.25-2.0 mg)
Trial: 2390255
Drug: Thiopental sodium
RxNorm normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental sodium by infusion throughout CPB (n = 52)
Trial: 2390255
Drug: Thiopental sodium
RxNorm normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental sodium 15 mg/kg by bolus before aortic declamping (n = 48)
Trial: 6115596
Drug: Morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine + Placebo
Trial: 6115596
Drug: Morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine + Cimetidine (H2)
Trial: 6115596
Drug: Morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine + Diphenhydramine (H1)
Trial: 6115596
Drug: Morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine + Cimetidine (H2) + Diphenhydramine (H1)
Trial: 28216232
Drug: BIIB074 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB074 150 mg three times per day for 21 days, followed by random assignment to BIIB074 or placebo for up to 28 days.
Trial: 25552403
Drug: 850 mg
RxNorm normalized name: bran 850 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 850 mg metformin hydrochloride administered p.o. in the evening of day 4 and in the morning of day 5
Trial: 25552403
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg trimethoprim administered p.o. twice daily for 5 days
Trial: 23967069
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (school-delivered sexuality programming)
Trial: 679592
Drug: Phase I
RxNorm normalized name: Nuvelle TS Phase I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I drug testing program
Trial: 8889673
Drug: Intranasal heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal heroin (6 mg)
Trial: 8889673
Drug: Intranasal heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal heroin (12 mg)
Trial: 8889673
Drug: Intramuscular heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular heroin (6 mg)
Trial: 8889673
Drug: Detection times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection times for total morphine by GC‐MS and immunoassay (300‐ng/mL cutoff concentration)
Trial: 1988535
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with morphine sulfate (MS) alone
Trial: 1988535
Drug: PCA plus
RxNorm normalized name: PCA Plus 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA plus continuous infusion of morphine sulfate (PCA + CI)
Trial: 29891957
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy and behaviour change counselling
Trial: 26823037
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basic therapies only)
Trial: 25190744
Drug: High-Intensity Concurrent
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Concurrent Training (HICT) consisting of two weekly sessions of speed endurance training (SET) followed by heavy resistance training (HRT) and two weekly sessions of aerobic training
Trial: 25190744
Drug: High-Intensity Concurrent
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Concurrent Training (HICT)
Trial: 15255784
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (960 micro g d(‐1), 3 months)
Trial: 9014483
Drug: Beni-koji aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beni-koji aqueous extracts (27 g of beni-koji eq. per day) for 8 weeks
Trial: 1551349
Drug: Metoclopramide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (40 mg/day)
Trial: 1551349
Drug: Domperidone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (80 mg/day)
Trial: 3924720
Drug: Intravenous nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nutritional repletion with dextrose providing 0.95 times baseline resting energy expenditure
Trial: 3924720
Drug: Intravenous nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nutritional repletion with dextrose providing 1.75 times baseline resting energy expenditure
Trial: 19346114
Drug: Betaine-rich diet
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine-rich diet (approximately 800 mg/day)
Trial: 19346114
Drug: Betaine supplement
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine supplement (0.5 g twice daily)
Trial: 19346114
Drug: Control (pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pre-treatment values)
Trial: 3323165
Drug: Roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 300 mg daily
Trial: 3323165
Drug: Roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 150 mg bd
Trial: 30137297
Drug: Behavioural intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioural intervention in pregnancy with online support; Duration: Not specified; Dosage: Not specified
Trial: 30137297
Drug: Online support;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online support; Duration: Not specified; Dosage: Not specified
Trial: 24095588
Drug: Omega-3 LCPUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 LCPUFA supplementation (277.8mg DHA and 39.0mg EPA/capsule)
Trial: 21782381
Drug: Hydroxypropyl methylcellulose
RxNorm normalized name: HYDROXYPROPYL METHYLCELLULOSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxypropyl methylcellulose (HPMC) 2% gel (Cornea_Protect)
Trial: 17065697
Drug: Dietary, drug,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary, drug, and insulin treatments
Trial: 15079008
Drug: Cannabis extract
RxNorm normalized name: Cannabis sativa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis extract (oral cannador)
Trial: 10075068
Drug: Sufentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (1 microg/kg bolus followed by 0.005 microg/kg/min infusion)
Trial: 10075068
Drug: Fentanyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (10 microg/kg bolus followed by 0.075 microg/kg/min infusion)
Trial: 10075068
Drug: Alfentanil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (100 microg/kg bolus followed by 0.7 microg/kg/min infusion)
Trial: 1828366
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil with continuous epidural infusion of 0.125% bupivacaine
Trial: 1828366
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil with continuous intravenous infusion of 0.125% bupivacaine
Trial: 6785099
Drug: Intravenously infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously infused saralasin (dose 0.01‐10 microgram kg‐1 min‐1)
Trial: 6785099
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of saralasin at the highest dose directly into the renal artery of denervated kidneys
Trial: 31586293
Drug: Methimazole (MMI)
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole (MMI) 10 mg for 6 weeks prior to 131I therapy
Trial: 23783643
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ofloxacin (200 mg) and roxithromycin (150 mg) twice daily for 3 months
Trial: 23783643
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ofloxacin and roxithromycin
Trial: 20957498
Drug: mosapride 5
RxNorm normalized name: mosapride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mosapride 5 mg thrice daily
Trial: 11473681
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide 0.5 mg twice daily for 1 month followed by 0.25 mg daily for the next 2 months
Trial: 11473681
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide 0.1 mg twice daily throughout the 3-month treatment period
Trial: 11473681
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (high-dose and low-dose)
Trial: 9440663
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir for the prevention of CMV infection
Trial: 3263868
Drug: MDP-Lys(L18) 200
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MDP-Lys(L18) 200 micrograms (multiple 5 day administration)
Trial: 3263868
Drug: MDP-Lys(L18) (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDP-Lys(L18) (high-dose group)
Trial: 5297559
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (for negative reactors)
Trial: 5297559
Drug: Smallpox vaccine
RxNorm normalized name: SMALLPOX VACCINE
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smallpox vaccine
Trial: 5297559
Drug: Smallpox vaccine
RxNorm normalized name: SMALLPOX VACCINE
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smallpox vaccine with BCG for negative reactors
Trial: 30093799
Drug: Resonance Voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resonance Voice Therapy (RVT)
Trial: 30093799
Drug: Cervical-thoracic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical-thoracic therapy
Trial: 19914051
Drug: Dexamethasone 5
RxNorm normalized name: dexamethasone 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg IV (Group D; n = 30)
Trial: 12690049
Drug: Morphine-6-beta-glucuronide (M6G)
RxNorm normalized name: TETRAHYDROCURCUMIN .BETA.-O-GLUCURONIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-6-beta-glucuronide (M6G) infusion (low dose, 2 hours)
Trial: 12690049
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion (positive control)
Trial: 1345035
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (2 g per day)
Trial: 31138316
Drug: Continued SDZ
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued SDZ ETN (50 mg subcutaneous once-weekly)
Trial: 31138316
Drug: Switched to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switched to SDZ ETN (50 mg subcutaneous once-weekly)
Trial: 27176631
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with clonidine (15 μg mL-1)
Trial: 27176631
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with epinephrine (12.5 μg mL-1)
Trial: 23949563
Drug: Standard-volume split-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-volume split-dose polyethylene glycol with standard diet (SV-PEG with SD)
Trial: 19413144
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - sleep education, stimulus control, and time‐in‐bed restrictions; 20 patients with primary insomnia and 21 with comorbid insomnia
Trial: 11713064
Drug: Topical fluorometholone
RxNorm normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical fluorometholone (FML) six times daily for 4 weeks (group 1)
Trial: 11713064
Drug: Topical fluorometholone
RxNorm normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical fluorometholone (FML) three times daily for 4 weeks (group 2)
Trial: 9334554
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg of methylphenidate twice per day
Trial: 9334554
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg of methylphenidate twice per day
Trial: 3720365
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine at regular intervals
Trial: 3720365
Drug: Subcutaneous nicomorphine
RxNorm normalized name: nicomorphine
DrugBank: Nicomorphine (DB13454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous nicomorphine on demand
Trial: 25970759
Drug: Topical haemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical haemoglobin spray
Trial: 21504072
Drug: Cefixim 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixim 400 mg/day for 5 days
Trial: 21504072
Drug: Ciprofloxacin 250‐500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250‐500 mg twice a day for 5 days
Trial: 19352378
Drug: Walnut group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut group (30 g per day walnuts)
Trial: 9591737
Drug: Glucagon infusion
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon infusion at 0.4 ng x kg(‐1) x min(‐1)
Trial: 9591737
Drug: Glucagon infusion
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon infusion at 1.2 ng x kg(‐1) x min(‐1)
Trial: 9591737
Drug: Higher rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher rate of glucagon infusion (1.2 ng x kg(‐1) x min(‐1))
Trial: 26965560
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (solifenacin 5 mg + mirabegron 50 mg)
Trial: 23084955
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy with adjunctive manual therapy (ET+MT)
Trial: 21199294
Drug: Single-dose tenofovir/emtricitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose tenofovir/emtricitabine (TDF/FTC)
Trial: 14506195
Drug: 186Re-labeled BIWA
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 186Re-labeled BIWA 4 (bivatuzumab) at doses of 20, 30, 40, 50, and 60 mCi/m2
Trial: 10699324
Drug: cpts 248/404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cpts 248/404 RSV vaccine
Trial: 10699324
Drug: sequential immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential immunization
Trial: 8867548
Drug: Discontinued low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued low dose methotrexate (MTX) prior to and during surgery (Group 1, n = 19)
Trial: 8867548
Drug: Continued low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued low dose methotrexate (MTX) throughout the perioperative period (Group 2, n = 13)
Trial: 2258342
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of pefloxacin 800 mg
Trial: 2258342
Drug: Five-day treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-day treatment with norfloxacin 400 mg twice daily
Trial: 6987112
Drug: Rifamycin SV
RxNorm normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifamycin SV by intramuscular injection and topically
Trial: 6987112
Drug: Rifamycin SV
RxNorm normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifamycin SV by injection only
Trial: 6987112
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment used at the particular centre